Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRP019
MIFTS: 58

Peripheral Nervous System Disease

Categories: Immune diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Peripheral Nervous System Disease

About this section

MalaCards integrated aliases for Peripheral Nervous System Disease:

Name: Peripheral Nervous System Disease 12 15 17
Peripheral Neuropathy 12 74 53 29 6 17 71
Peripheral Nerve Disorders 42
Peripheral Nerve Disease 12
Neuropathy, Peripheral 39

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:574
ICD10 32 G64
UMLS 71 C0031117 C1335029
Sources

Summaries for Peripheral Nervous System Disease

About this section
NINDS : 53 Peripheral neuropathy refers to the many conditions that involve damage to the peripheral nervous system, which sends signals between the brain and spinal cord and all other parts of the body. Neuropathy means damage to one or more nerves, especially the peripheral nerves. More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms and prognosis. Impaired function and symptoms depend on the type of nerves that are damaged. Symptoms of neuropathy range from mild to disabling and may include a loss of reflexes, problems feeling pain or changes in temperature, numbness and tingling, and pain that is often worse at night. Symptoms may develop over days, weeks, or years. In some cases, the symptoms improve on their own and may not require advanced care. Causes of neuropathy include: diabetes physical injury (trauma) vascular and blood problems autoimmune disorders nutritional or vitamin imbalances, alcoholism, and exposure to toxins certain chemotherapy drugs infections  Most instances of neuropathy are either acquired, meaning the neuropathy isn’t present from the beginning of life, or genetic.  Acquired neuropathies are either symptomatic (the result of another disorder or condition) or idiopathic (meaning it has no known cause).

MalaCards based summary : Peripheral Nervous System Disease, also known as peripheral neuropathy, is related to autoimmune peripheral neuropathy and rare peripheral neuropathy, and has symptoms including seizures, tremor and back pain. An important gene associated with Peripheral Nervous System Disease is NEFL (Neurofilament Light), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Aztreonam and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and brain.

Disease Ontology : 12 A nervous system disease that affects the peripheral nervous system.

MedlinePlus : 42 Your peripheral nerves are the ones outside your brain and spinal cord. Like static on a telephone line, peripheral nerve disorders distort or interrupt the messages between the brain and the rest of the body. There are more than 100 kinds of peripheral nerve disorders. They can affect one nerve or many nerves. Some are the result of other diseases, like diabetic nerve problems. Others, like Guillain-Barre syndrome, happen after a virus infection. Still others are from nerve compression, like carpal tunnel syndrome or thoracic outlet syndrome. In some cases, like complex regional pain syndrome and brachial plexus injuries, the problem begins after an injury. Some people are born with peripheral nerve disorders. Symptoms often start gradually, and then get worse. They include Numbness Pain Burning or tingling Muscle weakness Sensitivity to touch Treatment aims to treat any underlying problem, reduce pain and control symptoms. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 74 Peripheral neuropathy, often shortened to neuropathy, is a general term describing disease affecting the... more...

Sources

Related Diseases for Peripheral Nervous System Disease

About this section

Diseases in the Peripheral Nervous System Disease family:

Autoimmune Disease of Peripheral Nervous System

Diseases related to Peripheral Nervous System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1407)
# Related Disease Score Top Affiliating Genes
1 autoimmune peripheral neuropathy 35.5 MPZ ICOSLG GJB1
2 rare peripheral neuropathy 35.3 NGLY1 NEFL IARS2 HARS1 CHRNG
3 motor peripheral neuropathy 35.2 PMP22 MFN2 GJB1 DCAF8
4 neuropathy, hereditary, with liability to pressure palsies 34.2 PMP22 NEFL MPZ MFN2 GJB1
5 hypertrophic neuropathy of dejerine-sottas 34.0 PMP22 NEFL MPZ MFN2 GJB1
6 charcot-marie-tooth disease, axonal, type 2w 33.9 MPZ MFN2 HARS1 GJB1
7 chediak-higashi syndrome 33.9 SERPINA3 ICOSLG H2AC18 CCR6
8 neuropathy, congenital hypomyelinating, 1, autosomal recessive 33.8 PMP22 NEFL MPZ MFN2 GJB1 DCAF8
9 charcot-marie-tooth disease, axonal, type 2b 33.6 NEFL MPZ GJB1
10 foot drop 33.5 PMP22 MPZ
11 charcot-marie-tooth disease, x-linked dominant, 1 33.3 PMP22 NEFL MPZ MFN2 GJB1
12 charcot-marie-tooth disease and deafness 33.3 PMP22 NEFL MPZ MFN2 GJB1
13 polyradiculoneuropathy 33.2 PMP22 MPZ ICOSLG
14 charcot-marie-tooth disease, dominant intermediate c 33.1 MPZ GJB1 EPRS1
15 charcot-marie-tooth disease, axonal, type 2b2 33.1 NEFL MPZ MFN2
16 wolfram syndrome 33.0 MT-ND4 INS CRYAA
17 myofibrillar myopathy 32.9 SERPINA3 DCAF8 CRYAA
18 optic nerve disease 32.4 SERPINA3 NEFL MT-ND4 MFN2 ICOSLG ERCC6
19 nervous system disease 32.3 SERPINA3 ICOSLG H2AC18 ERCC6 EPRS1 DCAF8
20 charcot-marie-tooth disease, demyelinating, type 1a 32.3 PMP22 NEFL MPZ MFN2 GJB1
21 charcot-marie-tooth disease, axonal, type 2j 32.3 NEFL MPZ
22 neuromuscular disease 32.1 SERPINA3 PMP22 NEFL MPZ MFN2 H2AC18
23 autosomal recessive disease 32.0 SERPINA3 ICOSLG H2AC18 ERCC6 EPRS1 CRYAA
24 pulmonary disease, chronic obstructive 31.9 SERPINA3 INS ICOSLG H2AC18 EPRS1 CCR6
25 microcephaly 31.9 NGLY1 MT-ND4 MFN2 HARS1 H2AC18 ERCC6
26 neuropathy 31.9 PMP22 NEFL MT-ND4 MPZ MFN2 IARS2
27 autosomal dominant cerebellar ataxia 31.9 SERPINA3 H2AC18 ERCC6 CRYAA
28 eye disease 31.9 SERPINA3 MT-ND4 INS ICOSLG H2AC18 ERCC6
29 systemic scleroderma 31.8 INS ICOSLG H2AC18 CCR6
30 charcot-marie-tooth disease, demyelinating, type 1b 31.8 PMP22 MPZ MFN2 GJB1
31 central nervous system disease 31.8 SERPINA3 ICOSLG H2AC18 ERCC6 EPRS1 CRYAA
32 exanthem 31.7 ICOSLG H2AC18 CCR6
33 amyotrophic lateral sclerosis 1 31.7 SERPINA3 NEFL H2AC18 ERCC6 EPRS1 CRYAA
34 ptosis 31.7 MT-ND4 GJB1 ERCC6 CRYAA CHRNG
35 acute cystitis 31.6 SERPINA3 INS H2AC18 EPRS1 CCR6
36 myelitis 31.6 ICOSLG CCR6 AQP4
37 retinitis pigmentosa 31.6 SERPINA3 MT-ND4 INS HARS1 H2AC18 ERCC6
38 demyelinating disease 31.6 SERPINA3 PMP22 MPZ ICOSLG H2AC18 CCR6
39 charcot-marie-tooth disease 31.6 PMP22 NEFL MPZ MFN2 HARS1 H2AC18
40 mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 31.6 MT-ND4 INS IARS2 EPRS1
41 leukodystrophy 31.5 SERPINA3 MPZ GJB1 ERCC6 EPRS1 CRYAA
42 guillain-barre syndrome 31.4 PMP22 MPZ CCR6
43 chronic inflammatory demyelinating polyradiculoneuropathy 31.4 PMP22 MPZ ICOSLG
44 pelizaeus-merzbacher disease 31.4 SERPINA3 PMP22 MPZ H2AC18 ERCC6
45 collagen disease 31.4 SERPINA3 H2AC18 CCR6
46 motor neuron disease 31.4 NEFL MPZ MFN2 INS H2AC18
47 polyneuropathy 31.4 PMP22 MPZ MFN2 INS GJB1
48 body mass index quantitative trait locus 11 31.4 SERPINA3 MFN2 INS ICOSLG H2AC18 CCR6
49 sensory peripheral neuropathy 31.4 PMP22 MPZ MFN2 GJB1
50 distal arthrogryposis 31.3 SERPINA3 IARS2 H2AC18 CHRNG

Graphical network of the top 20 diseases related to Peripheral Nervous System Disease:



Diseases related to Peripheral Nervous System Disease
Sources

Symptoms & Phenotypes for Peripheral Nervous System Disease

About this section

UMLS symptoms related to Peripheral Nervous System Disease:


seizures, tremor, back pain, headache, syncope, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, neuralgia, neurologic symptoms, atypical facial pain
Sources

Drugs & Therapeutics for Peripheral Nervous System Disease

About this section

Drugs for Peripheral Nervous System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 513)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Ofloxacin Approved Phase 4 82419-36-1 4583
5
Histamine Approved, Investigational Phase 4 51-45-6 774
6
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
7
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
8
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
9
Capsaicin Approved Phase 4 404-86-4 1548943
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
12
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
13
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
14
Racepinephrine Approved Phase 4 329-65-7 838
15
Zidovudine Approved Phase 4 30516-87-1 35370
16
Lopinavir Approved Phase 4 192725-17-0 92727
17
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
18
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
19
Norepinephrine Approved Phase 4 51-41-2 439260
20
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
21
Lenalidomide Approved Phase 4 191732-72-6 216326
22
Ixazomib Approved, Investigational Phase 4 1072833-77-2
23
Ethanol Approved Phase 4 64-17-5 702
24
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
25
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
26
Tapentadol Approved Phase 4 175591-23-8 9838022
27
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
28
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
29
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
30
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
31
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
32
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
33
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
34 Anticholesteremic Agents Phase 4
35 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
36 Anti-Allergic Agents Phase 4
37 Histamine H1 Antagonists Phase 4
38 Histamine H1 Antagonists, Non-Sedating Phase 4
39 Histamine Antagonists Phase 4
40
Histamine Phosphate Phase 4 51-74-1 65513
41 Excitatory Amino Acid Antagonists Phase 4
42 Angiotensin-Converting Enzyme Inhibitors Phase 4
43 Narcotic Antagonists Phase 4
44 Adrenergic alpha-Agonists Phase 4
45 Adrenergic beta-Agonists Phase 4
46 Vasoconstrictor Agents Phase 4
47 Epinephryl borate Phase 4
48 Anti-Asthmatic Agents Phase 4
49 Adrenergic Agonists Phase 4
50 Bronchodilator Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 960)
# Name Status NCT ID Phase Drugs
1 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
2 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
3 Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY Unknown status NCT00235222 Phase 4 stavudine
4 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Surgery in Patients With Suppurative or Gangrenous Appendicitis Unknown status NCT03380793 Phase 4 morinidazole
5 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease Unknown status NCT03391440 Phase 4 morinidazole
6 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
7 A Multicenter, Double-blind, Randomized, Placebo and Active-controlled Study of Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
8 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
9 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
10 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
11 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
12 High-dose Vitamin D Supplementation Reduces Inflammation and Improves Microcirculation in Patients With Diabetic Peripheral Neuropathy Completed NCT04377399 Phase 4 Vitamin D
13 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
14 L-Arginine and Endothelial Dysfunction in Type 2 Diabetic Patients Completed NCT00902616 Phase 4
15 A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain Completed NCT00407511 Phase 4 Pregabalin
16 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
17 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
18 An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
19 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
20 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
21 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
22 A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
23 A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment Completed NCT01675531 Phase 4 Targin
24 The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Patients With Diabetic Peripheral Neuropathic Pain: a Randomized, Placebo-controlled Study of South Asian Male Patients Completed NCT04238208 Phase 4 Lidocaine 5% patch;Capsaicin 8% Patch, Per 10 Square Centimeters
25 A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
26 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
27 Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy: A Randomized, Double Blind, Placebo Controlled, Multi Center Trial Completed NCT02923388 Phase 4 Injection Mecobalamin,;Tablet Pyridoxine hydrochloride;Intravenous normal saline 1 ml;Placebo pill
28 Comparison of the Analgesic Effect of the Local Anesthetics Ropicacaine, Levobupivacaine, and Levobupivacaine + Epinephrin Via Interscalene Nerve Block in Patients Undergoing Shoulder Arthroscopy Under General Anesthesia Completed NCT02691442 Phase 4 Ropivacaine 0.75%;Levobupivacaine 0.5%;Levobupivacaine 0.5% + epinephrin 1/200000
29 Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
30 Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide (Prialt®)- The Swedish Ziconotide Bolus Study Completed NCT01373983 Phase 4 Ziconotide
31 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
32 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Without Comorbid Major Depressive Disorder Completed NCT00401258 Phase 4 duloxetine
33 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
34 Pilot Phase IV, Multicenter, Randomized, Open-label and Controlled Study to Assess the Evolution of Peripheral Body Fat Distribution After Switching From Zidovudine Containing Backbone to Truvada in HIV-1-infected Patients on HAART (RECOMB Study). Completed NCT00324649 Phase 4 Truvada;Zidovudine/lamivudine
35 Randomized Double-blind Study Comparing the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component Completed NCT01166048 Phase 4 Duloxetine;Duloxetine
36 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
37 Exploratory, Cross-sectional Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy Completed NCT01116817 Phase 4 Lumbar puncture (Lopinavir/ritonavir monotherapy);Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI)
38 Evaluation of Safety and Efficacy of Raltegravir/Darunavir Combination in Antiretroviral-Naive Patients Completed NCT00677300 Phase 4 Raltegravir;Darunavir;Ritonavir;Tenofovir/Emtricitabine
39 Randomised and Prospective Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens Completed NCT00994344 Phase 4 Darunavir/ritonavir;Lopinavir/ritonavir
40 Comparison of the Steady State Pharmacokinetics of Nevirapine, Stavudine Plus Lamivudine in HIV Positive Ugandan Patients Taking Triomune 40 With the Pharmacokinetics of the Originator Products. Completed NCT00455585 Phase 4 nevirapine, stavudine, lamivudine
41 A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT) Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
42 The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty: A Double-Blinded Randomized Controlled Trial Completed NCT00620828 Phase 4 Ropivicaine 0.5%
43 Effect of Myofascial Release on Electrophysiological and Clinical Measures of Pregnant Women With Carpal Tunnel Syndrome Completed NCT03802448 Phase 4
44 A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination With Lenalidomide for Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Recruiting NCT04217967 Phase 4 Ixazomib;Lenalidomide
45 Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM) Recruiting NCT04246619 Phase 4 Pregabalin;Duloxetine
46 Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
47 URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence Active, not recruiting NCT03302299 Phase 4 Isoniazid 300 Mg ORAL TABLET;Pyridoxine 25 Mg Oral Tablet
48 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial Enrolling by invitation NCT03271151 Phase 4 Cymbalta
49 Precision Spinal Cord Stimulation for Painful Diabetic Neuropathy Terminated NCT00487981 Phase 4
50 A Randomized, Double-Blind, Placebo-Controlled Trial Of The Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy Symptoms In Subjects With Advanced Colorectal Cancer Terminated NCT00380874 Phase 4 Pregabalin;Placebo

Search NIH Clinical Center for Peripheral Nervous System Disease

Sources

Genetic Tests for Peripheral Nervous System Disease

About this section

Genetic tests related to Peripheral Nervous System Disease:

# Genetic test Affiliating Genes
1 Peripheral Neuropathy 29
Sources

Anatomical Context for Peripheral Nervous System Disease

About this section

MalaCards organs/tissues related to Peripheral Nervous System Disease:

40
Breast, Lung, Brain, Testes, Spinal Cord, Skin, Bone
Sources

Publications for Peripheral Nervous System Disease

About this section

Articles related to Peripheral Nervous System Disease:

(show top 50) (show all 17972)
# Title Authors PMID Year
1
Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy. 61 42
32384502 2020
2
Endoscopic Carpal Tunnel Release: Indications, Technique, and Outcomes. 42
32498954 2020
3
Study on efficacy and safety of Huangqi Guizhi Wuwu decoction treatment for oxaliplatin induced peripheral neurotoxicity: A protocol for a randomized, controlled, double-blind, multicenter trial. 42
32481364 2020
4
The effect of rat nerve growth factor combined with vitamin B on peripheral neuropathy in multiple myeloma patients. 61
32567522 2020
5
mTOR activation by constitutively active serotonin6 receptors as new paradigm in neuropathic pain and its treatment. 61
32512114 2020
6
Insights into platinum-induced peripheral neuropathy-current perspective. 61
32209761 2020
7
Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity. 61
32416186 2020
8
The isoform-specific functions of the c-Jun N-terminal kinase (JNK) in a mouse model of antiretroviral-induced painful peripheral neuropathy. 61
32416188 2020
9
Escin alleviates peripheral neuropathy in streptozotocin induced diabetes in rats. 61
32407839 2020
10
Metformin protects from oxaliplatin induced peripheral neuropathy in rats. 61
32490289 2020
11
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. 61
32502876 2020
12
Central nervous system complications associated with immune checkpoint inhibitors. 61
32312871 2020
13
Linear mixed-effects models for the analysis of high-density electromyography with application to diabetic peripheral neuropathy. 61
32447652 2020
14
Protective effect of quercetin on streptozotocin-induced diabetic peripheral neuropathy rats through modulating gut microbiota and reactive oxygen species level. 61
32559841 2020
15
IFN-γ/mTORC1 decreased Rab11 in Schwann cells of diabetic peripheral neuropathy, inhibiting cell proliferation via GLUT1 downregulation. 61
31970777 2020
16
Low brain-derived neurotrophic factor protein levels and single-nucleotide polymorphism Val66Met are associated with peripheral neuropathy in type II diabetic patients. 61
32124075 2020
17
A recessive Trim2 mutation causes an axonal neuropathy in mice. 61
32205255 2020
18
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. 61
32170867 2020
19
A Randomized Controlled Trial to Assess the Effectiveness of Muscle Strengthening and Balancing Exercises on Chemotherapy-Induced Peripheral Neuropathic Pain and Quality of Life Among Cancer Patients. 61
30888982 2020
20
Topical Delivery of Muscarinic Receptor Antagonists Prevents and Reverses Peripheral Neuropathy in Female Diabetic Mice. 61
32327528 2020
21
Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives. 61
32352155 2020
22
Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. 61
32315091 2020
23
cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons. 61
32087251 2020
24
The LFA-1 antagonist BIRT377 reverses neuropathic pain in prenatal alcohol-exposed female rats via actions on peripheral and central neuroimmune function in discrete pain-relevant tissue regions. 61
31918004 2020
25
Treatment of diabetic peripheral neuropathy: a review. 61
32067247 2020
26
Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. 61
32546132 2020
27
COVID 19 infection presenting as motor peripheral neuropathy. 61
32354690 2020
28
Somatic Mutations Confer Severe Peripheral Neuropathy in POEMS Syndrome-Associated Multicentric Castleman Disease. 61
32166648 2020
29
Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study. 61
32529585 2020
30
Optimised cushioning in diabetic footwear can significantly enhance their capacity to reduce plantar pressure. 61
32454304 2020
31
Clustering classification of diabetic walking abnormalities: a new approach taking into account intralimb coordination patterns. 61
32334348 2020
32
A modulator of the low-voltage activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies. 61
32541387 2020
33
Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study. 61
32576561 2020
34
Young-onset type 2 diabetes and younger current age: increased susceptibility to retinopathy in contrast to other complications. 61
31968129 2020
35
The protective effect of modafinil on vincristine-induced peripheral neuropathy in rats: A possible role for TRPA1 receptors. 61
32542990 2020
36
[Three Cases of Augmented Chemotherapy-Induced Peripheral Neuropathy after Changing from mFOLFOX6 to FOLFIRI Therapy in Patients with Colorectal Cancer]. 61
32541182 2020
37
Comment on Retinal and Corneal Neurodegeneration and Its Association to Systemic Signs of Peripheral Neuropathy in Type 2 Diabetes. 61
32536412 2020
38
microRNA-9 and -29a regulate the progression of diabetic peripheral neuropathy via ISL1-mediated sonic hedgehog signaling pathway. 61
32544883 2020
39
Measuring vincristine-induced peripheral neuropathy in children with cancer: validation of the Dutch pediatric-modified Total Neuropathy Score. 61
31732853 2020
40
Effect of diverse physical rehabilitative interventions on static postural control in diabetic peripheral neuropathy: a systematic review. 61
29979897 2020
41
Sensorimotor and gait training improves proprioception, nerve function, and muscular activation in patients with diabetic peripheral neuropathy: a randomized control trial. 61
32481239 2020
42
Whole body vibration showed beneficial effect on pain, balance measures and quality of life in painful diabetic peripheral neuropathy: a randomized controlled trial. 61
32550157 2020
43
Classification of functionality of people with diabetic peripheral neuropathy based on international classification of functioning, disability and health Core set (ICF-CS) of diabetes mellitus. 61
32550170 2020
44
A Secondary Analysis from a Randomized Trial on the Effect of Plasma Tetrahydrocannabinol Levels on Pain Reduction in Painful Diabetic Peripheral Neuropathy. 61
32565122 2020
45
The bone marrow-derived mesenchymal stem cells (BMSCs) alleviate diabetic peripheral neuropathy induced by STZ via activating GSK-3β/β-catenin signaling pathway. 61
32502517 2020
46
Reply to Comment on: Retinal and Corneal Neurodegeneration and Its Association to Systemic Signs of Peripheral Neuropathy in Type 2 Diabetes. 61
32536415 2020
47
Lycopene protects against central and peripheral neuropathy by inhibiting Oxaliplatin-induced ATF-6 pathway, apoptosis, inflammation and oxidative stress in brains and sciatic tissues of rats. 61
32544411 2020
48
Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study. 61
32193049 2020
49
Effectiveness of acupuncture combined mecobalamin in the treatment of elderly diabetic peripheral neuropathy: A protocol of systematic review and meta-analysis. 61
32501981 2020
50
Prophylactic efficacy of ninjin'yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2). 61
32232692 2020
Sources

Variations for Peripheral Nervous System Disease

About this section

ClinVar genetic disease variations for Peripheral Nervous System Disease:

6 (show top 50) (show all 81) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NGLY1 NM_018297.4(NGLY1):c.1533_1536del (p.Asn511fs)deletion Pathogenic 548658 rs765211108 3:25770699-25770702 3:25729208-25729211
2 HARS1 NM_002109.6(HARS1):c.616G>T (p.Asp206Tyr)SNV Pathogenic 804285 5:140057507-140057507 5:140677922-140677922
3 HARS1 NM_002109.6:c.730delGdeletion Pathogenic 804286
4 IARS2 NM_018060.4(IARS2):c.2726C>T (p.Pro909Leu)SNV Pathogenic 156553 rs587783070 1:220316451-220316451 1:220143109-220143109
5 46;XX;inv(7)(q11.23q36.3)dninversion Pathogenic 267882
6 NEFL NM_006158.5(NEFL):c.64C>T (p.Pro22Ser)SNV Pathogenic/Likely pathogenic 14029 rs28928910 8:24813966-24813966 8:24956452-24956452
7 CHRNG NM_005199.5(CHRNG):c.256C>T (p.Arg86Cys)SNV Pathogenic/Likely pathogenic 397615 rs777219451 2:233405327-233405327 2:232540617-232540617
8 COX6A1 NM_004373.4(COX6A1):c.103+1G>CSNV Likely pathogenic 560368 rs377504835 12:120876033-120876033 12:120438230-120438230
9 PMP2 NM_002677.5(PMP2):c.128T>A (p.Ile43Asn)SNV Likely pathogenic 243087 rs879253869 8:82357170-82357170 8:81444935-81444935
10 SPTLC3 NM_018327.4(SPTLC3):c.448T>C (p.Trp150Arg)SNV Likely pathogenic 243088 rs755919784 20:13053048-13053048 20:13072400-13072400
11 NEB NM_001271208.2(NEB):c.16637G>A (p.Arg5546His)SNV Conflicting interpretations of pathogenicity 257765 rs201111610 2:152435919-152435919 2:151579405-151579405
12 NEB NM_001271208.2(NEB):c.21902C>T (p.Pro7301Leu)SNV Conflicting interpretations of pathogenicity 387835 rs367626762 2:152384038-152384038 2:151527524-151527524
13 DNAJB5 NM_001135005.3(DNAJB5):c.43C>T (p.Pro15Ser)SNV Conflicting interpretations of pathogenicity 243086 rs774909609 9:34990670-34990670 9:34990673-34990673
14 LMNA NM_170707.4(LMNA):c.344A>T (p.Glu115Val)SNV Conflicting interpretations of pathogenicity 200932 rs794728588 1:156085053-156085053 1:156115262-156115262
15 SPTAN1 NM_001130438.3(SPTAN1):c.4039G>A (p.Asp1347Asn)SNV Conflicting interpretations of pathogenicity 207286 rs574740801 9:131367749-131367749 9:128605470-128605470
16 ABCA4 NM_000350.3(ABCA4):c.203C>T (p.Pro68Leu)SNV Conflicting interpretations of pathogenicity 99113 rs62654397 1:94577093-94577093 1:94111537-94111537
17 DNM2 NM_001005360.2(DNM2):c.190G>A (p.Val64Ile)SNV Conflicting interpretations of pathogenicity 133978 rs144250390 19:10870442-10870442 19:10759766-10759766
18 LMNA NM_170707.4(LMNA):c.1634G>A (p.Arg545His)SNV Conflicting interpretations of pathogenicity 163878 rs142191737 1:156107470-156107470 1:156137679-156137679
19 MEFV NM_000243.3(MEFV):c.2084A>G (p.Lys695Arg)SNV Conflicting interpretations of pathogenicity 2547 rs104895094 16:3293403-3293403 16:3243403-3243403
20 ABCA4 NM_000350.3(ABCA4):c.2588G>C (p.Gly863Ala)SNV Conflicting interpretations of pathogenicity 7879 rs76157638 1:94517254-94517254 1:94051698-94051698
21 FLRT1 NM_014067.4(MACROD1):c.517+34908C>TSNV Conflicting interpretations of pathogenicity 530943 rs143337663 11:63883803-63883803 11:64116331-64116331
22 FLRT1 NM_014067.4(MACROD1):c.517+34743C>TSNV Uncertain significance 530937 rs770193280 11:63883968-63883968 11:64116496-64116496
23 FLRT1 NM_014067.4(MACROD1):c.517+33591C>TSNV Uncertain significance 530934 rs138289564 11:63885120-63885120 11:64117648-64117648
24 FLRT1 NM_014067.4(MACROD1):c.517+33852C>GSNV Uncertain significance 530941 rs138445479 11:63884859-63884859 11:64117387-64117387
25 FLRT1 NM_014067.4(MACROD1):c.517+33260C>ASNV Uncertain significance 530936 rs143309484 11:63885451-63885451 11:64117979-64117979
26 FLRT1 NM_014067.4(MACROD1):c.517+33192T>CSNV Uncertain significance 530940 rs150249733 11:63885519-63885519 11:64118047-64118047
27 FLRT1 NM_014067.4(MACROD1):c.517+34934G>ASNV Uncertain significance 530938 rs139768227 11:63883777-63883777 11:64116305-64116305
28 FLRT1 NM_014067.4(MACROD1):c.517+34449C>TSNV Uncertain significance 530935 rs148012979 11:63884262-63884262 11:64116790-64116790
29 KCNJ10 NM_002241.5(KCNJ10):c.967T>C (p.Tyr323His)SNV Uncertain significance 816536 1:160011356-160011356 1:160041566-160041566
30 FLRT1 NM_014067.4(MACROD1):c.517+34721G>ASNV Uncertain significance 857225 11:63883990-63883990 11:64116518-64116518
31 FLRT1 NM_014067.4(MACROD1):c.517+34501G>TSNV Uncertain significance 842634 11:63884210-63884210 11:64116738-64116738
32 FLRT1 NM_014067.4(MACROD1):c.517+33995C>TSNV Uncertain significance 859555 11:63884716-63884716 11:64117244-64117244
33 FLRT1 NM_014067.4(MACROD1):c.517+33326G>ASNV Uncertain significance 835656 11:63885385-63885385 11:64117913-64117913
34 FLRT1 NM_014067.4(MACROD1):c.517+33197C>TSNV Uncertain significance 845837 11:63885514-63885514 11:64118042-64118042
35 FLRT1 NM_014067.4(MACROD1):c.517+33180C>TSNV Uncertain significance 840095 11:63885531-63885531 11:64118059-64118059
36 FLRT1 NM_014067.4(MACROD1):c.517+34761C>GSNV Uncertain significance 530933 rs777177875 11:63883950-63883950 11:64116478-64116478
37 FLRT1 NM_014067.4(MACROD1):c.517+33617C>TSNV Uncertain significance 530939 rs150825004 11:63885094-63885094 11:64117622-64117622
38 MYBPC3 NM_000256.3(MYBPC3):c.3614G>A (p.Arg1205Gln)SNV Uncertain significance 181014 rs730880596 11:47354130-47354130 11:47332579-47332579
39 KIF24 deletion Uncertain significance 243059 9:34280042-34296294 9:34280044-34296296
40 FLRT1 NM_014067.4(MACROD1):c.517+34535G>ASNV Uncertain significance 579757 rs756250929 11:63884176-63884176 11:64116704-64116704
41 FLRT1 NM_014067.4(MACROD1):c.517+34898_517+34918deldeletion Uncertain significance 571356 rs1565240655 11:63883793-63883813 11:64116321-64116341
42 FLRT1 NM_014067.4(MACROD1):c.517+34196G>ASNV Uncertain significance 566239 rs776773158 11:63884515-63884515 11:64117043-64117043
43 FLRT1 NM_014067.4(MACROD1):c.517+33881C>TSNV Uncertain significance 565723 rs767022154 11:63884830-63884830 11:64117358-64117358
44 FLRT1 NM_014067.4(MACROD1):c.517+33719C>TSNV Uncertain significance 568577 rs769032516 11:63884992-63884992 11:64117520-64117520
45 FLRT1 NM_014067.4(MACROD1):c.517+33604C>ASNV Uncertain significance 566560 rs1395376914 11:63885107-63885107 11:64117635-64117635
46 FLRT1 NM_014067.4(MACROD1):c.517+34250T>ASNV Uncertain significance 577882 rs1565241569 11:63884461-63884461 11:64116989-64116989
47 FLRT1 NM_014067.4(MACROD1):c.517+33243C>TSNV Uncertain significance 575806 rs140274429 11:63885468-63885468 11:64117996-64117996
48 FLRT1 NM_014067.4(MACROD1):c.517+34305T>CSNV Uncertain significance 643512 11:63884406-63884406 11:64116934-64116934
49 FLRT1 NM_014067.4(MACROD1):c.517+34236G>ASNV Uncertain significance 647420 11:63884475-63884475 11:64117003-64117003
50 FLRT1 NM_014067.4(MACROD1):c.517+33906T>GSNV Uncertain significance 640772 11:63884805-63884805 11:64117333-64117333

Copy number variations for Peripheral Nervous System Disease from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 107001 17 11200000 15900000 Copy number Peripheral neuropathy
Sources

Expression for Peripheral Nervous System Disease

About this section
Search GEO for disease gene expression data for Peripheral Nervous System Disease.
Sources

Pathways for Peripheral Nervous System Disease

About this section

Pathways related to Peripheral Nervous System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neural Crest Differentiation 1
10.81 PMP22 MPZ GJB1
Sources

GO Terms for Peripheral Nervous System Disease

About this section

Biological processes related to Peripheral Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tRNA aminoacylation for protein translation GO:0006418 8.8 IARS2 HARS1 EPRS1

Molecular functions related to Peripheral Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 aminoacyl-tRNA ligase activity GO:0004812 8.8 IARS2 HARS1 EPRS1
Sources

Sources for Peripheral Nervous System Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....